Racura Appoints Contract Research Organisation for Lung Cancer Trial

MT Newswires Live

2025/12/24

Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.

The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.

The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2593449591"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593449591\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593449591?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 07:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593449591","market":"us","top_or_hot":-1,"title":"Racura Appoints Contract Research Organisation for Lung Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.</p><p>The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.</p><p>The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Appoints Contract Research Organisation for Lung Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Appoints Contract Research Organisation for Lung Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-24 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.</p><p>The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.</p><p>The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593449591","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593449591","pubTimestamp":1766532203,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Racura任命肺癌试验合同研究组织","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Racura Oncology (ASX:RAC) appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}